bioAffinity Technologies Secures $1.8 Million Direct Financing for Noninvasive Cancer Detection Test bioAffinity Technologies has successfully closed a $1.8 million financing round, aimed at enhancing its revolutionary lung cancer detection test, CyPath® Lung.

bioAffinity Technologies Secures $1.8 Million Direct Financing for Noninvasive Cancer Detection Test #USA #Jersey_City #WallachBeth #bioAffinity #CyPath